JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, published by Oxford University Press Inc, stands as a pivotal resource for advancing research and knowledge in the domains of neuropathology and experimental neurology. Established in 1942, this esteemed journal has expanded its influence, as evidenced by its Q1 rankings in both Neurology (clinical) and Pathology and Forensic Medicine, along with its strong placement in Cellular and Molecular Neuroscience. With an emphasis on innovative research and clinical practices, it caters to a diverse audience, including researchers and clinicians dedicated to understanding neurological disorders through a multidisciplinary lens. While not open access, this journal provides access to cutting-edge studies that are pivotal in shaping the future of medical science and pathology. Researchers benefit from its rigorous peer-review process, ensuring the publication of high-caliber work that meets the evolving demands of the field.

NEUROMOLECULAR MEDICINE, published by HUMANA PRESS INC, is a prestigious peer-reviewed journal dedicated to advancing the fields of cellular and molecular neuroscience, molecular medicine, and neurology. With an ISSN of 1535-1084 and an E-ISSN of 1559-1174, the journal boasts a significant presence in academic research since its inception in 2002 and continues to publish cutting-edge studies through 2024. Ranked in the Q2 category for 2023 in various disciplines, including Neuroscience and Molecular Medicine, it holds impressive positions in Scopus rankings, including 41st out of 192 in Neuroscience and Neurology. Although not an open access journal, NEUROMOLECULAR MEDICINE remains invaluable for researchers, professionals, and students seeking to explore the intricate relationships between molecular mechanisms and neurological functions, thereby contributing to the scientific understanding of nervous system diseases and therapeutic innovations.

Neurology-Neuroimmunology & Neuroinflammation, published by LIPPINCOTT WILLIAMS & WILKINS, stands at the forefront of research in the rapidly evolving fields of neurology and neuroimmunology. Since its inception in 2014, this prestigious journal has embraced an Open Access model, ensuring that groundbreaking findings are readily available to researchers, clinicians, and students worldwide. Covering a broad spectrum of topics related to neuroinflammation, the journal has gained a remarkable reputation, attaining a Q1 ranking in both Neurology and Neurology (clinical) as of 2023, and ranking #6 out of 192 in the neuroscience category on Scopus. The journal's commitment to high-quality research aims to facilitate the understanding of neurological disorders, promote innovative therapies, and inspire collaboration among professionals. Addressing critical issues at the intersection of neurology, immunology, and clinical practice, Neurology-Neuroimmunology & Neuroinflammation is an essential platform for the dissemination of knowledge and the advancement of this vital field.

Translational Neurodegeneration, an esteemed journal in the field of neuroscience, is published by BMC and has been an open access platform since 2012, delivering high-quality research from its base in the United Kingdom. With an impressive impact factor reflecting its significant contributions, this journal focuses on critical advancements in cellular and molecular neuroscience, cognitive neuroscience, and clinical neurology, boasting a Q1 ranking across all these categories as of 2023. Researchers and professionals benefit from its extensive reach, characterized by exceptional Scopus rankings that place it in the top percentile of its field. The journal serves as a vital resource for academics and healthcare practitioners alike, aiming to bridge the gap between laboratory discoveries and clinical applications, thereby enhancing understanding and treatment of neurodegenerative diseases. With its commitment to open access, Translational Neurodegeneration ensures that its published research is accessible to a global audience, promoting collaboration and knowledge exchange within the scientific community.

ACTA NEUROPATHOLOGICA, published by Springer, is a leading journal in the fields of cellular and molecular neuroscience, clinical neurology, and pathology, recognized for its exceptional quality and impactful research. With an impressive impact factor and currently ranked in the Q1 tier across multiple categories in 2023, this journal serves as a premier platform for the dissemination of groundbreaking findings in neuropathology. The journal's robust Scopus rankings highlight its influence, standing at #2 in Pathology and Forensic Medicine and #5 in Clinical Neurology. Since its inception in 1961, ACTA NEUROPATHOLOGICA has provided crucial insights into neurological diseases and disorders, contributing significantly to the advancement of medical science. Aimed at researchers, practitioners, and students alike, this journal fosters a deeper understanding of neurological conditions and encourages innovative approaches within the field. It is essential reading for anyone dedicated to unraveling the complexities of the nervous system.

The INTERNATIONAL JOURNAL OF NEUROSCIENCE, published by TAYLOR & FRANCIS LTD, stands as a vital resource in the field of neuroscience since its inception. With a proud history of publication from 1970 to 2024, this journal is committed to advancing knowledge in various domains of neuroscience, from fundamental research to clinical applications. It is indexed with an ISSN of 0020-7454 and an E-ISSN of 1563-5279, reflecting its wide reach and recognition. The journal maintains a respectable position in the academic landscape, categorized as Q2 in Medicine (miscellaneous) and Q3 in Neuroscience (miscellaneous) as of 2023, signifying its relevance among researchers and professionals. Although it currently does not offer open access, the journal remains a significant platform for disseminating groundbreaking research, thereby fostering collaboration and innovation within the neuroscience community. Located in the United Kingdom, the journal aims to bridge gaps in neuroscience knowledge, making it an essential reading for students, professionals, and researchers dedicated to unraveling the complexities of the nervous system.

Welcome to the Journal of Central Nervous System Disease, a premier Open Access publication dedicated to advancing the understanding of neurological disorders and their underlying mechanisms. Published by SAGE Publications Ltd, this esteemed journal has been serving the scientific community since 2009 and is committed to disseminating high-quality research that spans from clinical neurology to cellular and molecular neuroscience. With an impressive impact factor, the journal ranks within the top quartiles—Q2 in both Neurology and Clinical Neurology, and Q3 in Cellular and Molecular Neuroscience as of 2023. The journal's indexing in Scopus reflects its significant contribution to the field, being ranked #83 out of 400 in clinical neurology and #38 out of 97 in cellular and molecular neuroscience. This essential resource, based in the United States, is crucial for researchers, clinicians, and students looking to stay at the forefront of neurological science. By providing Open Access options, we ensure that groundbreaking research is readily available to a global audience, fostering collaboration and innovation in the study of central nervous system diseases.

Neurotherapeutics, published by Springer, is a leading Open Access journal dedicated to the field of neurology and pharmacology, specifically focusing on innovative therapeutic approaches for neurological disorders. With an impressive impact factor and recognized as a prestigious outlet in its domain—ranking Q1 in Neurology (Clinical) and Pharmacology—this journal serves as an invaluable resource for researchers, healthcare professionals, and students aiming to stay updated with the latest advancements in neurotherapeutics. Since its inception in 2007 and now transitioning to Open Access from 2024, Neurotherapeutics enhances accessibility to high-quality research, ensuring that critical findings reach a global audience. Its current Scopus rankings further underscore its significance, placing it within the top echelons of pharmacology and clinical neurology. By fostering a robust platform for the dissemination of pioneering research, Neurotherapeutics plays a crucial role in shaping the future of neurological treatment and care.

Fluids and Barriers of the CNS is a premier open-access journal published by BMC, dedicated to advancing the field of neuroscience by exploring the complexities of the fluid dynamics and barriers of the central nervous system. Since its inception in 2011, the journal has established itself as a vital resource for researchers, professionals, and students alike, providing a platform for innovative research and critical discussions in areas such as cellular and molecular neuroscience, developmental neuroscience, neurology, and miscellaneous medicine. With an impressive Q1 ranking across multiple categories in 2023, and strong performance metrics such as being ranked in the 93rd percentile in Developmental Neuroscience, this journal not only highlights cutting-edge research but also contributes to the ongoing dialogue surrounding neurophysiology and pathology. As an open-access journal based in London, United Kingdom, it ensures that high-quality research is accessible to a global audience, fostering collaboration and knowledge-sharing in the neuroscientific community.

European Neurology, published by KARGER, is a distinguished journal in the field of neurology, catering to both clinical and neuroscience specialties. Since its inception in 1897 and continuing through 2024, the journal has been a vital platform for disseminating significant research findings and insights in neurology. With an ISSN of 0014-3022 and E-ISSN of 1421-9913, it ranks in the Q3 quartile in both clinical neurology and general neurology categories, reflecting its commitment to scholarly excellence while holding the 175th rank in clinical medicine and the 93rd in neuroscience, according to Scopus metrics. European Neurology facilitates a deeper understanding of neurological disorders and treatments, appealing to a diverse readership that includes researchers, clinicians, and students alike. Despite not currently offering open access, the journal’s rigorous peer-review process ensures that only high-quality research reaches its audience, making it an essential resource for those looking to stay informed in the rapidly evolving field of neurology.